Pulmatrix (NASDAQ:PULM) Stock Crosses Above 50-Day Moving Average – Should You Sell?

Pulmatrix, Inc. (NASDAQ:PULM) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $4.78 and traded as high as $4.80. Pulmatrix shares last traded at $4.49, with a volume of 14,966 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a report on Thursday, November 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Pulmatrix Trading Up 3.9%

The stock has a market capitalization of $16.39 million, a PE ratio of -2.64 and a beta of 1.64. The firm has a 50-day moving average price of $4.78 and a 200-day moving average price of $5.74.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new position in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent SEC filing. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.